Stocks · News reference

BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

Aug 3, 2026, 10:35 AMBenzinga Newsdesk

BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 3, 2026, 10:35 AM
Checked: Aug 3, 2026, 10:35 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 15, 2026, 11:20 AMBenzinga Newsdesk
Castle Biosciences Says 699-Patient Decision Modeling Study Shows TissueCypher Would Raise Appropriate Barrett's Esophagus Management From 59.8% To 75.3%; Escalation In Non-Dysplastic Progressors From 30.4% To 56.9%
CSTL
BenzingaSep 8, 2026, 1:43 PMBenzinga Newsdesk
SciBase Announces Additional Order From Castle Biosciences Valued At About $0.6M For Nevisense Go Devices And Electrodes To Accelerate Ongoing Atopic Dermatitis Study, Prepare Second Study; Deliveries Expected To Begin Q4 2026
CSTL
BenzingaAug 17, 2026, 11:08 AMBenzinga Newsdesk
Castle Biosciences Approved For Dual Listing On Nasdaq Texas While Maintaining Primary Listing On Nasdaq Global Market
CSTL